補腎明目丸對糖尿病腎病Ⅲ期（腎虛血瘀證）患者TGF-β1、PKC的影響
發(fā)布時間：2019-06-19 04:23
【摘要】：目的:研究補腎明目丸對DKDⅢ期(腎虛血瘀證)患者TGF-β1、PKC的影響及其對腎臟的保護作用。方法:篩選出66例符合納入標準的DKDⅢ期(腎虛血瘀證)患者,按照隨機數(shù)字法分為治療組(33例)和對照組(33例),治療組在基礎治療基礎上加補腎明目丸,對照組只給予基礎治療,療程12周。以中醫(yī)癥候積分、Hb Alc、U-MA、尿β2-MG、Cysc、轉(zhuǎn)化生長因子β1(TGF-β1)、蛋白激酶C(PKC)作為療效評價指標,觀察其療效。結(jié)果:1.中醫(yī)癥候積分:治療后兩組中醫(yī)證候積分與治療前相比都有顯著下降(P0.01);但兩組治療后相比治療組下降的更加明顯(P0.05);治療組總有效率為87.1%,高于對照組的62.5%(P0.05)。2.U-MA、尿β2-MG、Cysc比較:治療組治療后U-MA、尿β2-MG、Cysc明顯低于治療前(P0.01);對照組治療后U-MA、Cysc明顯低于治療前(P0.01);對照組治療后尿β2-MG低于治療前(P0.05);治療組治療后U-MA、尿β2-MG、Cysc與對照組治療后相比,差異有統(tǒng)計學意義(P0.05)。3.血清TGF-β1:治療組治療后TGF-β1明顯低于治療前(P0.01);對照組治療后低于治療前(P0.05);兩組病人治療后相比,差異有統(tǒng)計學意義(P0.01)。4.血清PKC:兩組治療后PKC水平均明顯低于治療前(P0.01);治療組治療后低于對照組治療后,差異有統(tǒng)計學意義(P0.05)。5.Hb Alc:兩組Hb Alc治療后均明顯低于治療前(P0.01);但治療組治療后與對照組治療后相比差異無統(tǒng)計學意義(P0.05)。6.血脂:兩組治療后LDL-C、TG與治療前比較,差異無統(tǒng)計學意義(P0.05)。結(jié)論:補腎明目丸可以明顯的改善糖尿病腎病(腎虛血瘀證)患者的早期臨床相關癥狀。補腎明目丸能夠降低糖尿病腎病患者U-MA、尿β2-MG、Cysc、TGF-β1、PKC的水平,并且療效確切。
[Abstract]:Aim: to study the effect of Bushen Mingmu Pill on TGF- 尾 1 and PKC in patients with DKD stage III (kidney deficiency and blood stasis syndrome) and its protective effect on kidney. Methods: 66 patients with DKD stage III (kidney deficiency and blood stasis syndrome) were randomly divided into treatment group (n = 33) and control group (n = 33). The treatment group was supplemented with Bushen Mingmu pill on the basis of basic treatment, and the control group was only given basic treatment for 12 weeks. Hb Alc,U-MA, urine 尾 2-MG,Cysc, transforming growth factor 尾 1 (TGF- 尾 1) and protein kinase C (PKC) were used as therapeutic indexes to observe the curative effect of TCM syndrome score, urine 尾 2-transforming growth factor 尾 1 (TGF- 尾 1) and protein kinase C (PKC). Result: 1. TCM syndrome score: after treatment, the scores of TCM syndromes in both groups were significantly lower than those before treatment (P 0.01), but after treatment, the scores of TCM syndromes in the two groups were more obvious than those in the treatment group (P 0.05). The total effective rate of the treatment group was 87.1%, which was higher than that of the control group (62.5%). 2.U 鈮，
本文編號：2502086
[Abstract]:Aim: to study the effect of Bushen Mingmu Pill on TGF- 尾 1 and PKC in patients with DKD stage III (kidney deficiency and blood stasis syndrome) and its protective effect on kidney. Methods: 66 patients with DKD stage III (kidney deficiency and blood stasis syndrome) were randomly divided into treatment group (n = 33) and control group (n = 33). The treatment group was supplemented with Bushen Mingmu pill on the basis of basic treatment, and the control group was only given basic treatment for 12 weeks. Hb Alc,U-MA, urine 尾 2-MG,Cysc, transforming growth factor 尾 1 (TGF- 尾 1) and protein kinase C (PKC) were used as therapeutic indexes to observe the curative effect of TCM syndrome score, urine 尾 2-transforming growth factor 尾 1 (TGF- 尾 1) and protein kinase C (PKC). Result: 1. TCM syndrome score: after treatment, the scores of TCM syndromes in both groups were significantly lower than those before treatment (P 0.01), but after treatment, the scores of TCM syndromes in the two groups were more obvious than those in the treatment group (P 0.05). The total effective rate of the treatment group was 87.1%, which was higher than that of the control group (62.5%). 2.U 鈮，
本文編號：2502086
本文鏈接：http://sikaile.net/zhongyixuelunwen/2502086.html
最近更新
教材專著
